2Guidance for industry,Bioavailability and Bioequivalence Studies for Orally Administered Drug Products-General Considerations[S].2000:4
3Guidance for industry:Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a Biopharmaceutics Classification System[S].2000:1
4Amidon GL,Lennern? s H,Shah VP,et al.A theoretical basis for a Biopharmaceutics Drug Classification:The correlation of in vitro drug product dissolution and in vivo bioavailability[J].Pharm Res,1995,12:413
5The Biopharmaceutics Classification System (BCS) Guidance[S].2003:1
6PolliJE,Yu LX,Cook JA,et al.Summary Workshop Report:Biopharmaceutics Classification System -Implementation Challenges and Extension Opportunities[J].J Pharm Sci,2004,93:1375
7Oberle RL,Amidon GL.The influence of variable gastric emptying and intestinal transit rates on the plasma level curve of cimetidine; An explanation for the double peak phenomenon[J].J Pharmacokinet Biopharm,1987,15:529
8Yu LX,Lipka E,Crison JR,et al.Transport approaches to modeling the biopharmaceutical design of oral drug delivery systems:Prediction of intestinal drug absorption[J].Adv Drug Deliv Rev,1996,19:359
9Yazdanian M,Briggs K,Jankovsky C,et al.The" high solubility" definition of the current FDA Guidance on Biopharmaceutical Classification System may be too strict for acidic drugs[J].Pharm Res,2004,21:293
10Lobenberg R,Amidon GL.Modern bioavailability,bioequivalence and biopharmaceutics classification system.New scientific approaches to international regμlatory standards[J].Eur J Pharm Biopharm,2000,50:3
4Amidon GL,Lennern H,Shah VP,et al.A theoretical basisfor a biopharmaceutie drus classification:the correlation of in vitro drug product dissolution and in vivo bioavailability[J].Pharm Res,1995;12:413-420.
5US Department of Health and Human Services,Food and Drug Ad-ministration,Center for Drug Evaluation and Research(CDER).Guidance for industry:waiver of in vivo bioavailability and bioequiv-alence studies for immediate-release solid products,based on a biopharmaceutics classification system[EB/OL].http://www.fda.gov/cder/guidance/3618fnl.htm,2007-12-17.
6WHO Expert Committee on specifications for Pharmaceutical Prepa-rations:Fortieth Report;Annex 8.Proposal to waive in vivo bio-equivalence requirements for WHO Model List of Essential Medi-cines immediate-release,solid oral dosage forms[EB/OL].ht-tp://whqlibdoc.who.int/trs/WHO_TRS_937_eng.pdf,2008-12-15.
7EMEA,Committee for Proprietary Medicinal Products.Note for guidance on the investigation of bioequivalence[EB/OL].http://www.emea.europa.eu/pdfs/human/qwp/140198enfin.pdf,2008-07-24.
